Updates from Syncona and our portfolio companies
Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative research agreement with the Sheffield Institute for Translational Neuroscience (SITraN), an international centre of excellence within the University of Sheffield recognised for its ground-breaking work in the fight against neurodegenerative disorders. Under the terms of the agreement, Quell Therapeutics will collaborate in a joint research programme with SITraN to accelerate the validation of Quell’s engineered Treg cell therapy platform for use in the treatment of neuroinflammatory diseases.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Neogene Therapeutics, Inc., a biotechnology company pioneering a new class of fully personalized T cell therapies to treat cancer, today announced a broad strategic partnership. The companies will leverage Neogene’s proprietary expertise in targeting tumor neo-antigens, mutated proteins found in cancer cells due to cancer-associated DNA mutations, together with Twist’s DNA synthesis platform and product lines to develop personalized chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies for patients with cancer.
Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced the appointment of Professor Karl Peggs as Chief Medical Officer (CMO) with effect from 4th January 2021. Professor Peggs is an internationally recognised leader in the field of cancer immunology and a founder of the Company.
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of Franz B. Humer, Ph.D., as Executive Chairman of the Board of Directors. A world-renowned pharmaceutical industry trailblazer, Dr. Humer served as Chairman and Chief Executive Officer of Roche Holding, Ltd. over a period of 16 years before retiring in 2014. As a result of the recent Series A financing, Rachel Mears of Jeito Capital, Elisa Petris, Ph.D., of Syncona Investment Management Ltd., Caroline Stout of EcoR1 Capital, and Katherine Wood of TPG Capital, also have joined the Neogene Board.
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announces that Romuald Corbau, Ph.D. has been promoted to the role of Chief Scientific Officer. The Founder of Freeline, Professor Amit Nathwani, will continue in his role as Clinical and Scientific Adviser and member of the Board of Directors of the Company.
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical stage, fully-integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announces their supply agreement with Thermo Fisher Scientific Inc. (“Thermo Fisher”).
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is an investigational one-time AAV-based gene therapy that is delivered under the retina and is intended to slow the progression of GA that can lead to blindness.
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that it has raised $110 million in a Series A financing. The financing was co-led by EcoR1 Capital, Jeito Capital and Syncona, with participation from Polaris Partners and Pontifax. Seed investors Vida Ventures, TPG and Two River also participated in the round.